Last reviewed · How we verify
Ara-C±IDA
Ara-C±IDA is a combination chemotherapy regimen that inhibits DNA synthesis and induces apoptosis in rapidly dividing cells.
Ara-C±IDA is a combination chemotherapy regimen that inhibits DNA synthesis and induces apoptosis in rapidly dividing cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL).
At a glance
| Generic name | Ara-C±IDA |
|---|---|
| Also known as | Cytarabine, Idarubicin |
| Sponsor | Sunshine Lake Pharma Co., Ltd. |
| Drug class | Combination chemotherapy (nucleoside analog + anthracycline) |
| Target | DNA polymerase (Ara-C); Topoisomerase II (IDA) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ara-C (cytarabine) is a nucleoside analog that inhibits DNA polymerase and incorporates into DNA, causing chain termination and cell death. IDA (idarubicin) is a topoisomerase II inhibitor that prevents DNA unwinding and repair. Together, they provide synergistic cytotoxic effects against hematologic malignancies.
Approved indications
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Mucositis
- Nausea and vomiting
- Cardiotoxicity
- Hepatotoxicity
- Neurotoxicity (high-dose Ara-C)
Key clinical trials
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (PHASE1)
- BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (PHASE2)
- CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics (PHASE2)
- VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (PHASE3)
- Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) (PHASE2)
- Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML (PHASE3)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ara-C±IDA CI brief — competitive landscape report
- Ara-C±IDA updates RSS · CI watch RSS
- Sunshine Lake Pharma Co., Ltd. portfolio CI